BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Epizyme 

400 Technology Square
4th Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-500-7240 Fax: 617-349-0707


SEARCH JOBS



Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of our product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease affecting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment.

We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. When Epizyme was founded, we recognized that the HMT class of enzymes might contain many potential oncogenes and, therefore, presented the opportunity to discover, develop and commercialize multiple personalized therapeutics.

We have prioritized 20 HMTs as attractive targets for personalized therapeutics based on their oncogenic potential. Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). We believe that our ongoing Phase 1 study for EPZ-5676, targeting DOT1L, is the first clinical trial of an HMT inhibitor. We expect to initiate a Phase 1/2 clinical trial of EPZ-6438 targeting EZH2 in 2Q 2013.

We were founded in 2007 and are led by a management team with extensive experience in the pharmaceutical industry. We have entered into therapeutic collaborations with Celgene, Eisai and Glaxo Group Limited (an affiliate of GlaxoSmithKline), or GSK, that have provided us with approximately $120 million in non-equity funding through March 31, 2013. As of March 31, 2012, we had $85 million in cash and cash equivalents.


 Key Statistics


Email: Contact@Epizyme.com
Ownership:

Web Site: Epizyme
Employees: 66
Symbol: EPZM
 









 Company News
Epizyme (EPZM) Appoints Peter Ho, M.D., Ph.D., As Chief Development Officer And Michael Shih, J.D., As Vice President, Business Development 9/15/2014 10:22:27 AM
Epizyme (EPZM) Announces Resignation Of President And Chief Financial Officer Jason Rhodes 9/3/2014 1:03:44 PM
Epizyme (EPZM) To Present At Upcoming Conferences In September 8/26/2014 10:24:16 AM
Epizyme (EPZM) To Present At Upcoming Conferences In September 8/26/2014 9:54:43 AM
Epizyme (EPZM) Announces Second Quarter 2014 Financial Results And Provides Corporate Update 8/13/2014 7:51:08 AM
Epizyme (EPZM) Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At American Society of Hematology Meeting On Lymphoma Biology 8/13/2014 7:46:51 AM
Epizyme (EPZM) To Report Second Quarter Financial Results And Provide Corporate Update On August 13, 2014 7/28/2014 8:56:34 AM
Epizyme (EPZM) To Give Oral Presentation On Pre-Clinical Models And Early Clinical Observations Of EZH2 Inhibitor EPZ-6438 At American Society of Hematology Meeting On Lymphoma Biology August 10-13, 2014 6/10/2014 6:25:52 AM
Epizyme (EPZM) To Present At Upcoming Conferences In June 5/28/2014 6:52:17 AM
Epizyme (EPZM) Announces First Quarter 2014 Financial Results And Provides Corporate Update 5/14/2014 6:18:27 AM
12345678910